Literature DB >> 25486583

Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.

G M T Guilcher1, R Moorjani1, T H Truong1, V A Lewis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25486583     DOI： 10.1038/bmt.2014.272

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

2.  Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Timothy Madden; James A Russell; Richard E Champlin
Journal:  Curr Opin Oncol       Date:  2009-06       Impact factor: 3.645

3.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

Authors:  George B McDonald; John T Slattery; Michelle E Bouvier; Song Ren; Ami L Batchelder; Thomas F Kalhorn; H Gary Schoch; Claudio Anasetti; Ted Gooley
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

Review 4.  Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.

Authors:  Mignon L Loh
Journal:  Br J Haematol       Date:  2011-03       Impact factor: 6.998

5.  Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.

Authors:  Jean E Sanders; Ho Joon Im; Paul A Hoffmeister; Ted A Gooley; Ann E Woolfrey; Paul A Carpenter; Robert G Andrews; Eileen M Bryant; Frederick R Appelbaum
Journal:  Blood       Date:  2005-01-06       Impact factor: 22.113

6.  The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Authors:  James A Russell; William Irish; Alexander Balogh; M Ahsan Chaudhry; Mary Lynn Savoie; A Robert Turner; Loree Larratt; Jan Storek; Nizar J Bahlis; Christopher B Brown; Diana Quinlan; Michelle Geddes; Nancy Zacarias; Andrew Daly; Peter Duggan; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-03       Impact factor: 5.742

7.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

Authors:  Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

8.  Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Xuemei Wang; Daniel Couriel; Martin Korbling; Soonja Roberson; Sergio Giralt; Betty Pierre; James A Russell; Elizabeth J Shpall; Roy B Jones; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

9.  A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

Authors:  Miharu Yabe; Masahiro Sako; Hiromasa Yabe; Yuko Osugi; Hidemitsu Kurosawa; Taemi Nara; Mika Tokuyama; Souichi Adachi; Chie Kobayashi; Masakatsu Yanagimachi; Yoshitoshi Ohtsuka; Yozo Nakazawa; Chitose Ogawa; Atsushi Manabe; Seiji Kojima; Tatsutoshi Nakahata
Journal:  Pediatr Transplant       Date:  2008-04-06

Review 10.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418
View more
  1 in total

Review 1.  Two Different Transplant Preconditioning Regimens Combined with Irradiation and Chemotherapy in the Treatment of Childhood Leukemia: Systematic Review and Meta-Analysis.

Authors:  Xiangwen Wang; Dan Mu; Anyang Geng; Anqi Zhao; Yiyuan Song
Journal:  J Healthc Eng       Date:  2022-03-18       Impact factor: 2.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.